GeneDx Securities Class Action Reminder for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Deadline for Claims: Investors must file lead plaintiff applications for the GeneDx securities class action by August 3, 2026, concerning shares purchased between April 16, 2025, and May 4, 2026, or risk losing their right to recover losses.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin from 74% to 69% in its Q1 2026 results, missing revenue estimates for both its exome and genome lines, and lowered its full-year revenue guidance to $475-$490 million from $540-$550 million, indicating significant operational challenges.
- Stock Price Plunge: Following the disappointing earnings report, GeneDx's stock price fell by $33.42, or 49.2%, which not only reflects investor concerns about the company's financial health but may also impact investor confidence and future fundraising efforts.
- Impairment Loss Disclosure: The company disclosed a $31.2 million impairment loss related to its acquisition of Fabric Genomics, which was previously expected to expand its market and create sustainable revenue streams, but the current situation suggests it has failed to meet strategic expectations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 51.800
Low
155.00
Averages
171.43
High
200.00
Current: 51.800
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GeneDx Securities Class Action Reminder for Investors
- Deadline for Claims: Investors must file lead plaintiff applications for the GeneDx securities class action by August 3, 2026, concerning shares purchased between April 16, 2025, and May 4, 2026, or risk losing their right to recover losses.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin from 74% to 69% in its Q1 2026 results, missing revenue estimates for both its exome and genome lines, and lowered its full-year revenue guidance to $475-$490 million from $540-$550 million, indicating significant operational challenges.
- Stock Price Plunge: Following the disappointing earnings report, GeneDx's stock price fell by $33.42, or 49.2%, which not only reflects investor concerns about the company's financial health but may also impact investor confidence and future fundraising efforts.
- Impairment Loss Disclosure: The company disclosed a $31.2 million impairment loss related to its acquisition of Fabric Genomics, which was previously expected to expand its market and create sustainable revenue streams, but the current situation suggests it has failed to meet strategic expectations.
See More
GeneDx Faces Class Action Lawsuit Amid Significant Stock Drop
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against GeneDx Holdings Corp, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by August 3, 2026, indicating significant legal challenges ahead for the firm.
- Deteriorating Financials: GeneDx's Q1 2026 results revealed a drop in adjusted gross margin from 74% to 69%, with projected earnings revised down from $540-$555 million to $475-$490 million, highlighting a concerning decline in profitability.
- Acquisition Impact: The company reported a $31.3 million impairment loss directly linked to its acquisition of Fabric Genomics, which has raised further investor concerns regarding the financial implications of this strategic move.
- Stock Price Plunge: Following the earnings announcement, GeneDx's stock price plummeted by $33.42, or 49.20%, closing at $34.51 per share, reflecting a stark market reaction and pessimism about the company's future outlook.
See More
GeneDx Faces Class Action Lawsuit Reminder for Investors
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against GeneDx for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 16, 2025, and May 4, 2026, with a deadline to contact the firm by August 3, 2026.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin and lowered earnings projections in its Q1 2026 results on May 4, 2026, alongside a $31.3 million impairment related to Fabric Genomics, indicating a deterioration in the company's financial health.
- False Statement Allegations: The complaint alleges that GeneDx made false and misleading statements during the class period, resulting in investor losses when the truth emerged, highlighting significant failures in the company's disclosure practices.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected investors to contact them promptly to discuss their rights before certification, indicating potential risks the company faces regarding legal compliance.
See More
Badger Meter Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating Badger Meter, Inc. (NYSE: BMI) for potential breaches of fiduciary duties by its executives, which may lead shareholders to seek corporate reforms and fund recovery.
- Financial Performance Scrutiny: A recent securities class action alleges that Badger Meter's executives misled investors by attributing strong financial performance to sustainable demand-driven growth, while masking weakening demand trends.
- Performance Decline Impact: Following a series of disappointing quarterly reports in 2025 and 2026, Badger Meter's stock price significantly declined, severely undermining investor confidence in the company's future growth prospects and reflecting market concerns about its financial health.
- Potential Legal Consequences: Shareholders who purchased Badger Meter stock before April 18, 2024, and still hold shares can participate in the investigation and seek legal remedies, which may impact the company's governance structure and future direction.
See More
GeneDx Faces Securities Class Action After 49% Stock Drop
- Stock Price Crash: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 earnings report, leading to a securities class action representing investors who purchased shares between April 16, 2025, and May 4, 2026.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with the Fabric Genomics unit missing revenue expectations and incurring impairment charges of $31.2 million, representing about 94% of its acquisition cost, posing a significant threat to future financial health.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, significantly lower than previous forecasts, which may lead investors to question the company's future profitability.
- Legal Investigation Launched: Hagens Berman is investigating whether GeneDx intentionally or recklessly misled investors regarding the true value of Fabric Genomics and its impact on growth expectations, which could result in further legal repercussions and a decline in investor trust.
See More
GeneDx Faces Class Action Over Misleading Statements
- Acquisition Impact Investigation: Robbins LLP has filed a class action against GeneDx Holdings Corp. (WGS), alleging that the company misled investors regarding the positive financial impact of its April 2025 acquisition of Fabric Genomics, despite significant viability issues with Fabric that were allegedly known to the defendants.
- Declining Financial Performance: GeneDx reported in Q1 2026 that it missed revenue estimates for both its exome and genome lines, lowering its full-year revenue guidance to $475 million-$490 million from $540 million-$550 million, indicating that the acquisition did not yield the expected financial benefits.
- Stock Price Plummet: Following the disappointing financial results, GeneDx's stock price fell by $33.42, or 49.2%, reflecting severe market concerns about the company's future profitability and a significant loss of investor confidence.
- Legal Consequences: The class action lawsuit could expose GeneDx to substantial legal liabilities, allowing investors to seek compensation for losses incurred due to misleading statements, which may further impact the company's governance and executive accountability.
See More
GeneDx Securities Class Action Reminder for Investors
- Deadline for Claims: Investors must file lead plaintiff applications for the GeneDx securities class action by August 3, 2026, concerning shares purchased between April 16, 2025, and May 4, 2026, or risk losing their right to recover losses.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin from 74% to 69% in its Q1 2026 results, missing revenue estimates for both its exome and genome lines, and lowered its full-year revenue guidance to $475-$490 million from $540-$550 million, indicating significant operational challenges.
- Stock Price Plunge: Following the disappointing earnings report, GeneDx's stock price fell by $33.42, or 49.2%, which not only reflects investor concerns about the company's financial health but may also impact investor confidence and future fundraising efforts.
- Impairment Loss Disclosure: The company disclosed a $31.2 million impairment loss related to its acquisition of Fabric Genomics, which was previously expected to expand its market and create sustainable revenue streams, but the current situation suggests it has failed to meet strategic expectations.
See More
GeneDx Faces Class Action Lawsuit Amid Significant Stock Drop
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against GeneDx Holdings Corp, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by August 3, 2026, indicating significant legal challenges ahead for the firm.
- Deteriorating Financials: GeneDx's Q1 2026 results revealed a drop in adjusted gross margin from 74% to 69%, with projected earnings revised down from $540-$555 million to $475-$490 million, highlighting a concerning decline in profitability.
- Acquisition Impact: The company reported a $31.3 million impairment loss directly linked to its acquisition of Fabric Genomics, which has raised further investor concerns regarding the financial implications of this strategic move.
- Stock Price Plunge: Following the earnings announcement, GeneDx's stock price plummeted by $33.42, or 49.20%, closing at $34.51 per share, reflecting a stark market reaction and pessimism about the company's future outlook.
See More
GeneDx Faces Class Action Lawsuit Reminder for Investors
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against GeneDx for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 16, 2025, and May 4, 2026, with a deadline to contact the firm by August 3, 2026.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin and lowered earnings projections in its Q1 2026 results on May 4, 2026, alongside a $31.3 million impairment related to Fabric Genomics, indicating a deterioration in the company's financial health.
- False Statement Allegations: The complaint alleges that GeneDx made false and misleading statements during the class period, resulting in investor losses when the truth emerged, highlighting significant failures in the company's disclosure practices.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected investors to contact them promptly to discuss their rights before certification, indicating potential risks the company faces regarding legal compliance.
See More
Badger Meter Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating Badger Meter, Inc. (NYSE: BMI) for potential breaches of fiduciary duties by its executives, which may lead shareholders to seek corporate reforms and fund recovery.
- Financial Performance Scrutiny: A recent securities class action alleges that Badger Meter's executives misled investors by attributing strong financial performance to sustainable demand-driven growth, while masking weakening demand trends.
- Performance Decline Impact: Following a series of disappointing quarterly reports in 2025 and 2026, Badger Meter's stock price significantly declined, severely undermining investor confidence in the company's future growth prospects and reflecting market concerns about its financial health.
- Potential Legal Consequences: Shareholders who purchased Badger Meter stock before April 18, 2024, and still hold shares can participate in the investigation and seek legal remedies, which may impact the company's governance structure and future direction.
See More
GeneDx Faces Securities Class Action After 49% Stock Drop
- Stock Price Crash: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 earnings report, leading to a securities class action representing investors who purchased shares between April 16, 2025, and May 4, 2026.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with the Fabric Genomics unit missing revenue expectations and incurring impairment charges of $31.2 million, representing about 94% of its acquisition cost, posing a significant threat to future financial health.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, significantly lower than previous forecasts, which may lead investors to question the company's future profitability.
- Legal Investigation Launched: Hagens Berman is investigating whether GeneDx intentionally or recklessly misled investors regarding the true value of Fabric Genomics and its impact on growth expectations, which could result in further legal repercussions and a decline in investor trust.
See More
GeneDx Faces Class Action Over Misleading Statements
- Acquisition Impact Investigation: Robbins LLP has filed a class action against GeneDx Holdings Corp. (WGS), alleging that the company misled investors regarding the positive financial impact of its April 2025 acquisition of Fabric Genomics, despite significant viability issues with Fabric that were allegedly known to the defendants.
- Declining Financial Performance: GeneDx reported in Q1 2026 that it missed revenue estimates for both its exome and genome lines, lowering its full-year revenue guidance to $475 million-$490 million from $540 million-$550 million, indicating that the acquisition did not yield the expected financial benefits.
- Stock Price Plummet: Following the disappointing financial results, GeneDx's stock price fell by $33.42, or 49.2%, reflecting severe market concerns about the company's future profitability and a significant loss of investor confidence.
- Legal Consequences: The class action lawsuit could expose GeneDx to substantial legal liabilities, allowing investors to seek compensation for losses incurred due to misleading statements, which may further impact the company's governance and executive accountability.
See More
